Bursa Bölgesindeki süt sığırı işletmelerinde mastitise karşı hipramastivac ile aşılamanın profilaktik etkisi
Loading...
Files
Date
2005
Authors
Keskin, Abdülkadir
Journal Title
Journal ISSN
Volume Title
Publisher
Uludağ Üniversitesi
Abstract
Çalışmada polivalan bir mastitis aşısının (Hipramastivac®) saha şartlarında etkinliğinin araştırılması amaçlandı. Daha önce aşı uygulanmamış dört farklı işletmedeki 218 adet sağmal süt sığırı iki gruba ayrılarak aşı (n: 111) ve kontrol grupları (n: 107) oluşturuldu. Çalışma başlangıcında ineklerin bireysel Somatik Hücre Sayıları (SHS), California Mastitis Test (CMT) bulguları ve klinik mastitis vakaları belirlendi. Aşılama sonrası hayvanlar altı ay boyunca takip edilerek yukardaki bulgular yönünden aylık periyotlarda muayene edildi. CMT(+3) ve klinik mastitisli meme loblarından bakteriyolojik incelemeler için süt numuneleri alındı. Çalışma sonunda aşı grubunun somatik hücre sayısı ve CMT’ne göre subklinik mastitis oranı kontrol grubuna göre bir miktar düşük olmakla birlikte, gruplar arasındaki farklılıklar istatistiki açıdan önemsiz bulundu (P>0,05). Aşı grubunda toplam klinik mastitis %26,1, kontrol grubunda %18,7 olarak saptandı. Ancak gruplar arasındaki fark önemsiz bulundu (P>0,05). CMT(+3) pozitif meme loplarından alınan süt numunelerinde aşı ve kontrol grubunda sırasıyla %11,5 ve %15,6 Staphylococcus aureus (S. aureus) belirlendi. Tek kültür ve miks enfeksiyonlar şeklinde memede saptanan toplam Streptecoccus uberis (S. uberis) enfeksiyonu aşı grubunda %6,0 kontrol grubunda %4,3 olarak saptandı. Toplam Koagulaz Negatif Stafilokok (KNS) enfeksiyonu kontrol grubunda %6,2 aşı grubunda %9 olarak tespit edildi. Ancak S. aureus, S. uberis ve KNS enfeksiyonu bakımından gruplar arasında fark belirlenemedi. Aşının diğer komponentlerinin ilgili diğer bakterilere karşı koruma sağlayıp sağlamadığı değerlendirilemedi. Sonuç olarak; aşı grubunda meydana gelen klinik mastitislerin yangı derecesinin daha az ve iyileşme sürecinin daha hızlı olduğu kanısı uyanmakla birlikte, kullanılan polivalan mastitis aşısının mastitise karşı istenen düzeyde etkili olmadığı kanısına varıldı.
In this study, it was aimed to investigate the efficacy of a commercial polyvalent mastitis vaccine (Hipramastivac®) under field conditions. In four different dairy farms, 218 dairy cattle that previously received any mastitis vaccine, were separated into vaccine (n: 111) and control groups (n: 107). In the beginning of the study, individual Somatic Cell Count (SCC) and California Mastitis Tests (CMT) scores of animals and clinical mastitis cases were detected. After vaccination, animals were examined monthly for clinical findings mentioned above during six months. Milk samples were taken from udder quarters with CMT (+3) scores and clinical mastitis for bacteriological examination. At the end of the study, although subclinical mastitis according to SCC and CMT scores of vaccine group was lower than the control group, this was not statisticaly (P>0,05). Clinical mastitis was found to be at the rate of %26,1 and %18,7 in the vaccine and control groups. This difference was not also significant (P>0,05). Staphylococcus aureus (S. aureus) was isolated at the percentage of 11,5 and 15,6 in the vaccine and control groups, respectively, from milk samples of udder quarters with CMT (+3) scores. Streptecoccus uberis (S. uberis) in as pure culture and mix culture were detected from the vaccine and control groups as %6,0 and %4,3 respectively. Total Coagulase Negative Staphylococcus (CNS) infection were diagnosed in the vaccine and control groups as %9 and %6, respectively. This differences was not also significant between groups considering S. aureus, S. uberis and CNS infection. It was not evaluated whether to ensure the protection against to bacteria related to other vaccine components. However, clinical mastitis that occured in vaccine group seem to be had fewer inflamation degree and more rapid recovery period. It was concluded that polyvalent mastitis vaccine has not enough effective against mastitis.
In this study, it was aimed to investigate the efficacy of a commercial polyvalent mastitis vaccine (Hipramastivac®) under field conditions. In four different dairy farms, 218 dairy cattle that previously received any mastitis vaccine, were separated into vaccine (n: 111) and control groups (n: 107). In the beginning of the study, individual Somatic Cell Count (SCC) and California Mastitis Tests (CMT) scores of animals and clinical mastitis cases were detected. After vaccination, animals were examined monthly for clinical findings mentioned above during six months. Milk samples were taken from udder quarters with CMT (+3) scores and clinical mastitis for bacteriological examination. At the end of the study, although subclinical mastitis according to SCC and CMT scores of vaccine group was lower than the control group, this was not statisticaly (P>0,05). Clinical mastitis was found to be at the rate of %26,1 and %18,7 in the vaccine and control groups. This difference was not also significant (P>0,05). Staphylococcus aureus (S. aureus) was isolated at the percentage of 11,5 and 15,6 in the vaccine and control groups, respectively, from milk samples of udder quarters with CMT (+3) scores. Streptecoccus uberis (S. uberis) in as pure culture and mix culture were detected from the vaccine and control groups as %6,0 and %4,3 respectively. Total Coagulase Negative Staphylococcus (CNS) infection were diagnosed in the vaccine and control groups as %9 and %6, respectively. This differences was not also significant between groups considering S. aureus, S. uberis and CNS infection. It was not evaluated whether to ensure the protection against to bacteria related to other vaccine components. However, clinical mastitis that occured in vaccine group seem to be had fewer inflamation degree and more rapid recovery period. It was concluded that polyvalent mastitis vaccine has not enough effective against mastitis.
Description
Keywords
İnek, Mastitis, Aşılama, Cow, Vaccination
Citation
Keskin, A. (2005). Bursa Bölgesindeki süt sığırı işletmelerinde mastitise karşı hipramastivac ile aşılamanın profilaktik etkisi. Yayınlanmamış doktora tezi. Uludağ Üniversitesi Sağlık Bilimleri Enstitüsü.